Tech Company Financing Transactions
Vaxxas Funding Round
On 10/28/2025, Vaxxas raised $59 million in investment from private investors.
Transaction Overview
Company Name
Announced On
10/28/2025
Transaction Type
Venture Equity
Amount
$59,000,000
Round
Undisclosed
Investors
Proceeds Purpose
ObvioGo's decentralised trial capabilities will help to facilitate participation by a geographically diverse population in Vaxxas' clinical studies, essential to developing a vaccination technology for global health.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
47 Thorndike St. B1-1
Cambridge, MA 02141
USA
Cambridge, MA 02141
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Vaxxas is focussed on enhancing the performance of existing and next generation vaccines through the development and commercialization of the company's novel vaccine delivery technology - the Nanopatch.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Hoey
Chief Operating Officer
Angus Forster
VP - Engineering
Michael Junger
VP - Operations
Charles Ross
Browse more venture capital transactions:
Prev: 10/28/2025: RiPSIM Technologies venture capital transaction
Next: 10/28/2025: Syllo venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs